Evidence map›Paper›PMID 26814178›Full record

ArticlemBio2016

Characterization of a Multipeptide Lantibiotic Locus in Streptococcus pneumoniae.

Natalie Maricic, Erica S Anderson, AnneMarie E Opipari, Emily A Yu, Suzanne Dawid

Open access · goldAbstract read
In one paragraph

Article in mBio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 30 citations in OpenAlex.

  1. RggmBio · 2026
    Article
  2. Article
  3. Article
  4. Increasing prevalence of bacteriocin carriage in a six-year hospital cohort ofmedRxiv : the preprint server for health sciences · 2024
    Article
  5. Article
  6. Discovery of phosphorylated lantibiotics with proimmune activity that regulate the oral microbiome.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  7. Article
  8. Gene Expression Regulation in Airway Pathogens: Importance for Otitis Media.Frontiers in cellular and infection microbiology · 2022
    Review
  9. Intra-Species Interactions inFrontiers in cellular and infection microbiology · 2021
    Article
  10. The pneumococcal social network.PLoS pathogens · 2020
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Characterization of the Competitive Pneumocin Peptides ofFrontiers in cellular and infection microbiology · 2019
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Natalie MaricicDepartment of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA.
Erica S AndersonDepartment of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, Michigan, USA.
AnneMarie E OpipariDepartment of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, Michigan, USA.
Emily A YuDepartment of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, Michigan, USA.
Suzanne DawidDepartment of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, Michigan, USA sdawid@umich.edu.
University of Michigan–Ann Arbor · US

Funding

Cellular Biotechnology Training Program (CBTP)T32GM008353 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCHWENDEMAN, ANNA · 1991 to 2021
$9.3M
Cellular Biotechnology Training Program (CBTP) - Years 31-35T32GM145304 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Guizhi Zhu · 2022 to 2026
$2.6M
Bacterial and host factors in pneumococcal competitionR01AI078538 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI WEISER, JEFFREY NEAL · 2009 to 2013
$1.9M
Coordinate regulation of competence and pneumocin production in S. pneumoniaeR01AI101285 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DAWID, SUZANNE RACHEL · 2013 to 2017
$1.9M
NIAID NIH HHS R01 AI078538NIAID NIH HHS R01AI078538NIAID NIH HHS R01 AI101285NIGMS NIH HHS T32 GM008353NIGMS NIH HHS T32GM008353NIGMS NIH HHS T32 GM145304
6 · The paper itself

Abstract

unlabelledBacterial communities are established through a combination of cooperative and antagonistic interactions between the inhabitants. Competitive interactions often involve the production of antimicrobial substances, including bacteriocins, which are small antimicrobial peptides that target other community members. Despite the nearly ubiquitous presence of bacteriocin-encoding loci, inhibitory activity has been attributed to only a small fraction of gene clusters. In this study, we characterized a novel locus (the pld locus) in the pathogen Streptococcus pneumoniae that drives the production of a bacteriocin called pneumolancidin, which has broad antimicrobial activity. The locus encodes an unusual tandem array of four inhibitory peptides, three of which are absolutely required for antibacterial activity. The three peptide sequences are similar but appear to play distinct roles in regulation and inhibition. A modification enzyme typically found in loci encoding a class of highly modified bacteriocins called lantibiotics was required for inhibitory activity. The production of pneumolancidin is controlled by a two-component regulatory system that is activated by the accumulation of modified peptides. The locus is located on a mobile element that has been found in many pneumococcal lineages, although not all elements carry the pld genes. Intriguingly, a minimal region containing only the genes required for pneumolancidin immunity was found in several Streptococcus mitis strains. The pneumolancidin-producing strain can inhibit nearly all pneumococci tested to date and provided a competitive advantage in vivo. These peptides not only represent a unique strategy for bacterial competition but also are an important resource to guide the development of new antimicrobials. IMPORTANCE: Successful colonization of a polymicrobial host surface is a prerequisite for the subsequent development of disease for many bacterial pathogens. Bacterial factors that directly inhibit the growth of neighbors may provide an advantage during colonization if the inhibition of competitors outweighs the energy for production. In this work, we found that production of a potent antimicrobial called pneumolancidin conferred a competitive advantage to the pathogen Streptococcus pneumoniae. S. pneumoniae secreting pneumolancidin inhibits a wide array of Gram-positive organisms, including all but one tested pneumococcal strain. The pneumolancidin genetic locus is of particular interest because it encodes three similar modified peptides (lantibiotics), each of which has a distinct role in the function of the locus. Lantibiotics represent a relatively untapped resource for the development of clinically useful antibiotics which are desperately needed. The broad inhibitory activity of pneumolancidin makes it an ideal candidate for further characterization and development.

Indexed as

Genetic LociAmino Acid SequenceAntibiosisBacteriocinsGene Expression Regulation, BacterialGene OrderInterspersed Repetitive SequencesMicrobial Sensitivity TestsMolecular Sequence DataSequence AlignmentStreptococcus mitisStreptococcus pneumoniaeBacteriocins

Identifiers

PMID26814178
PMCPMC4742701
OpenAlexW2265996215

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.